If you've spent any time researching peptides, you've likely come across both BPC-157 and CJC-1295. They're two of the most commonly discussed performance peptides in Australia right now — and they come up together often enough that it's easy to assume they do the same thing.
They don't.
These are two distinct compounds with different mechanisms, different research profiles, and different primary applications. Understanding the difference helps you have a more informed conversation with a GP — and makes it less likely you'll pursue one when the other (or both) might be more appropriate.
Here's what the research has examined, how they compare, and how Australians are accessing them through medically supervised protocols.
The Quick Answer
BPC-157 and CJC-1295 work via completely different pathways.
BPC-157 is a body-protective compound with a research focus on repair — particularly gut lining integrity, tendon and ligament recovery, and tissue healing. CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that works by stimulating the pituitary gland to produce natural growth hormone pulses, with research examining effects on sleep quality, body composition, and recovery.
They're not interchangeable, but they're often prescribed together — because their effects may complement each other rather than overlap.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids. It was derived from a protein found naturally in gastric juice, which is part of what has made it interesting to researchers studying the gut.
Research has examined BPC-157 primarily in the context of:
Gut health and the gastrointestinal tract. Studies have examined its potential role in supporting the integrity of the gut lining and its association with reduced gut inflammation markers in animal models. The compound's origins in gastric protein make this one of the most biologically grounded areas of inquiry.
Tendon and ligament repair. A substantial portion of the animal model research on BPC-157 has examined its effects on tendon healing, with some studies observing accelerated recovery in surgically damaged tissue. This has made it of interest in sports medicine and recovery contexts.
Systemic tissue healing. More broadly, research has examined BPC-157's association with improved healing across various tissue types, including bone and muscle.
Neuroprotective properties. Some studies have examined potential effects on the nervous system, though this remains an earlier-stage area of inquiry.
It's important to note that the majority of BPC-157 research has been conducted in animal models, with limited published human clinical trial data. The mechanism is considered plausible and the preclinical data is substantial, but claims about human outcomes should be framed accordingly. BPC-157 is not a registered TGA medicine. In Australia, it is available via GP prescription through a licensed compounding pharmacy.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hormone that signals the pituitary gland to produce and release growth hormone (GH). Unlike synthetic growth hormone itself, CJC-1295 works by amplifying the body's own natural GH pulses rather than introducing exogenous growth hormone.
This is considered a more physiologically aligned approach — you're not replacing the body's signalling system, you're supporting it.
Research has examined CJC-1295 in the context of:
Growth hormone secretion. Clinical studies have demonstrated that CJC-1295 produces dose-dependent increases in GH and IGF-1 levels in humans. This is among the more robust areas of CJC-1295 research, including some published human data.
Sleep quality. Growth hormone is predominantly released during deep sleep. Research and clinical observation have associated improved GH pulsatility with improvements in sleep depth and recovery quality.
Body composition. CJC-1295 is often explored in the context of supporting lean muscle retention and fat metabolism — outcomes that are associated with healthy growth hormone levels, which naturally decline with age.
Recovery and energy. Patients in clinical settings often report improvements in energy, physical recovery, and general wellbeing, though individual responses vary and these outcomes are not guaranteed.
CJC-1295 is frequently paired with Ipamorelin — a growth hormone secretagogue — to produce a more complete GH pulse. This combination is common in Australian compounding protocols and is part of how the HPH Energy & Performance Protocol is structured.
Like BPC-157, CJC-1295 is not a registered TGA medicine and requires a valid GP prescription and licensed compounding pharmacy in Australia.
The Key Differences at a Glance
| BPC-157 | CJC-1295 | |
|---|---|---|
| Mechanism | Cytoprotective / tissue repair | GHRH analogue — stimulates pituitary GH release |
| Primary research focus | Gut health, tendon/ligament repair, tissue healing | Growth hormone pulsatility, body composition, sleep/recovery |
| Research base | Primarily animal models | Animal models + some human clinical data |
| Half-life | Short (hours) | Extended (~6–8 days with DAC modification) |
| Best suited to | Recovery, gut issues, tissue repair | Energy, sleep quality, body composition, healthy ageing |
Note: half-life and administration details should be confirmed with your prescribing GP, as compounded formulations may vary.
Can You Take Both?
Yes — and many people do.
BPC-157 and CJC-1295 target different systems and don't compete with one another mechanistically. In practice, they're often prescribed together when a patient's goals span both recovery/repair and performance/body composition.
Within the HPH Energy & Performance Protocol, the prescribing GP assesses your goals, bloodwork, health history, and lifestyle to determine which compounds are appropriate — and at what dose and frequency. Some patients are prescribed BPC-157 alone. Some CJC-1295 (with Ipamorelin). Some both. The protocol is personalised, not templated.
That's how it should work. Peptide combinations that make sense for one person may not be appropriate for another.
How to Find Out Which Is Right for You
The answer isn't on a forum, and it isn't in this article.
The right starting point is a clinical assessment with a GP who understands the research and can review your health history, your bloodwork, and your specific goals. Self-selecting compounds based on what you've read online carries real risks — not just to efficacy, but to your safety.
At High Performance Human, the assessment is the first step — not a formality. Our GPs review your full health picture before recommending anything. If peptide therapy isn't appropriate for you, they'll tell you.
View all protocols to understand what's available, or go straight to the assessment if you're ready.
Start Your Free Assessment
If you're based in Australia and want a proper clinical conversation about BPC-157, CJC-1295, or any of the protocols we offer — the first step is a free online assessment with one of our GPs.
No obligation. No pre-selected package you're being sold into. Just a real clinical conversation.
Real GP. Real prescription. Australian compounding pharmacy. That's what sets HPH apart.
This article is for informational purposes only and does not constitute medical advice. Peptide therapy must be prescribed by a registered Australian GP following a clinical assessment. Results may vary.